Premium
Combined chemotherapy of irinotecan and low‐dose cisplatin (I/low‐P) against metastatic biliary tract cancer
Author(s) -
Sugita Hiroki,
Hirota Masahiko,
Ichihara Atsushi,
Furuhashi Satoshi,
Kihara Shinichi,
Shimada Shinya
Publication year - 2006
Publication title -
journal of hepato‐biliary‐pancreatic surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.63
H-Index - 60
eISSN - 1868-6982
pISSN - 0944-1166
DOI - 10.1007/s00534-006-1098-0
Subject(s) - irinotecan , medicine , chemotherapy , cisplatin , regimen , biliary tract , gemcitabine , gastroenterology , biliary tract cancer , jaundice , cancer , oncology , gastrointestinal tract , surgery , colorectal cancer
There is no established or effective standard therapy for metastatic biliary tract cancer, resulting in poor prognosis. Recently, we performed combination chemotherapy of irinotecan and low‐dose cisplatin (I/low‐P) for three consecutive patients with metastatic biliary tract cancer. The regimen of I/low‐P therapy consisted of irinotecan (60 mg/m 2 ) and low‐dose cisplatin (6 mg/m 2 ), administered by intravenous infusion weekly or biweekly. Of the three patients, two showed a partial response, with durations of more than 20 months, and 2 months, respectively, while the third patient had stable disease for 3 months. One patient, who had jaundice, had grade 3 thrombocytopenia, but the other patients did not have any severe toxicities. Survival times were more than 20 months, 10 months, and 13 months, respectively. These outcomes suggest that I/low‐P therapy is safe and may be worth trying as a first‐line chemotherapy for patients with metastatic biliary tract cancer.